Lucid Diagnostics (LUCD), a subsidiary of PAVmed (PAVM), announced that the company will join the small-cap Russell 2000 Index and the broad-market Russell 3000 Index, effective after the close of U.S. equity markets on June 27, as part of their 2025 annual reconstitution, according to a preliminary list of additions posted by FTSE Russell on May 23.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LUCD:
- Lucid Diagnostics director buys $457.6K in common stock
- Lucid Diagnostics files to sell 36.98M shares of common stock for holders
- Lucid Diagnostics Reports Increased Losses Amid Revenue Decline
- Anticipated Medicare Coverage and Strategic Positioning Drive Buy Rating for Lucid Diagnostics
- Lucid Diagnostics: Strong Cash Position and Growing EsoGuard Test Volumes Justify Buy Rating